Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules
- PMID: 12789611
Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules
Abstract
The fundamental importance of angiogenesis in health and disease makes both inhibition and stimulation of blood vessel formation a major therapeutic goal. Vascular endothelial growth factor (VEGF) is the single most important angiogenic factor in disease-associated neovascularization and is both a major focus for the development of anti-angiogenic medicines for cancer and a candidate pro-angiogenic cytokine for the treatment of ischemic heart disease. The development of VEGF-specific or vascular-specific peptides is an emerging approach to the design of therapeutic molecules targeted against pathophysiological angiogenesis. This article highlights recent progress toward the development of anti-angiogenic and vascular-specific peptides with a focus on peptidic VEGF receptor antagonists.
Similar articles
-
The biology of VEGF and its receptors.Nat Med. 2003 Jun;9(6):669-76. doi: 10.1038/nm0603-669. Nat Med. 2003. PMID: 12778165 Review.
-
[Neoplasms and angiogenesis].Pol Merkur Lekarski. 2002 Sep;13(75):225-8. Pol Merkur Lekarski. 2002. PMID: 12474576 Review. Polish.
-
The molecular perspective: VEGF and angiogenesis.Stem Cells. 2003;21(1):118-9. doi: 10.1634/stemcells.21-1-118. Stem Cells. 2003. PMID: 12529559 No abstract available.
-
Vascular endothelial growth factor and its receptors in multiple myeloma.Leukemia. 2003 Oct;17(10):1961-6. doi: 10.1038/sj.leu.2403076. Leukemia. 2003. PMID: 14513045 Review.
-
VEGF and the quest for tumour angiogenesis factors.Nat Rev Cancer. 2002 Oct;2(10):795-803. doi: 10.1038/nrc909. Nat Rev Cancer. 2002. PMID: 12360282 Review.
Cited by
-
Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer.Cancer Res. 2010 Apr 1;70(7):2655-64. doi: 10.1158/0008-5472.CAN-09-4373. Epub 2010 Mar 23. Cancer Res. 2010. PMID: 20332242 Free PMC article.
-
Effective antitumour mono- and combination therapy by gene delivery of angiostatin-like molecule and interleukin-12 in a murine hepatoma model.Int J Colorectal Dis. 2005 Nov;20(6):494-501. doi: 10.1007/s00384-004-0727-9. Epub 2005 Apr 30. Int J Colorectal Dis. 2005. PMID: 15864607
-
Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer.World J Clin Oncol. 2014 Dec 10;5(5):1028-35. doi: 10.5306/wjco.v5.i5.1028. World J Clin Oncol. 2014. PMID: 25493238 Free PMC article. Review.
-
Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept.Int J Retina Vitreous. 2016 Feb 1;2:3. doi: 10.1186/s40942-016-0026-y. eCollection 2016. Int J Retina Vitreous. 2016. PMID: 27847621 Free PMC article. Review.
-
Serum tumor markers for detection of hepatocellular carcinoma.World J Gastroenterol. 2006 Feb 28;12(8):1175-81. doi: 10.3748/wjg.v12.i8.1175. World J Gastroenterol. 2006. PMID: 16534867 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources